Brainsway Ltd. ADR logo

Brainsway Ltd. ADR (BWAY)

Market Closed
2 Mar, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
23. 69
+0.55
+2.38%
$
453.81M Market Cap
- P/E Ratio
- Div Yield
115,414 Volume
-0.03 Eps
$ 23.14
Previous Close
Day Range
23.08 24.29
Year Range
7.84 26.63
Want to track BWAY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Upcoming BWAY split of 2:1 in 1 days (4 Mar 2026)
BWAY earnings report is expected in 7 days (10 Mar 2026)

Summary

BWAY closed today higher at $23.69, an increase of 2.38% from yesterday's close, completing a monthly increase of 3.63% or $0.83. Over the past 12 months, BWAY stock gained 23.77%.
BWAY is not paying dividends to its shareholders.
The last earnings report, released on Nov 12, 2025, missed the consensus estimates by -0.05%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports. The next scheduled earnings report is due on Mar 10, 2026.
Brainsway Ltd. ADR has a scheduled stock split on Mar 04, 2026 for a 2:1 split ratio, meaning every BWAY investor will receive 2.0 shares for every 1.0 existing shares.
Brainsway Ltd. ADR has completed 2 stock splits, with the recent split occurring on 5 hours ago.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

BWAY Chart

Similar

Ocular Therapeutix Inc.
$ 10.98
+22.82%
Aurinia Pharmaceuticals Inc.
$ 14.21
+0.28%
Vericel Corporation
$ 35.36
-0.9%
Relay Therapeutics Inc.
$ 9.79
-4.58%
Tandem Diabetes Care Inc.
$ 25.23
-0.28%
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens

BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens

BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.

Zacks | 2 months ago
BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

Seekingalpha | 3 months ago
BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

BrainsWay Ltd. ( BWAY ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Carl Byrnes - Northland Capital Markets, Research Division Raghuram Selvaraju - H.C.

Seekingalpha | 3 months ago

Brainsway Ltd. ADR (BWAY) FAQ

What is the stock price today?

The current price is $23.69.

On which exchange is it traded?

Brainsway Ltd. ADR is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is BWAY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 453.81M.

What is the earnings per share?

The EPS is 0.11.

When is the next earnings date?

The next earnings report will release on Mar 10, 2026.

Has Brainsway Ltd. ADR ever had a stock split?

Brainsway Ltd. ADR had 2 splits and the recent split was on 5 hours ago.

Brainsway Ltd. ADR Profile

Health Care Technology Industry
Healthcare Sector
Hadar Levy CEO
NASDAQ (NMS) Exchange
10501L106 CUSIP
IL Country
120 Employees
- Last Dividend
4 Mar 2026 Last Split
6 Oct 1999 IPO Date

Overview

BrainsWay Ltd. is a pioneering medical technology company focused on developing and providing noninvasive neurostimulation treatments for a variety of mental health disorders. Founded in 2003 and based in Jerusalem, Israel, the company has made significant strides in offering innovative healthcare solutions not only in the United States but also on an international scale. BrainsWay is dedicated to improving the lives of individuals suffering from mental health issues through its advanced Deep Transcranial Magnetic Stimulation (dTMS) platform technology. This commitment extends to a vast clientele including doctors, hospitals, and medical centers that specialize in psychiatry.

Products and Services

BrainsWay Ltd. offers a broad spectrum of treatments for mental health disorders through its flagship Deep Transcranial Magnetic Stimulation (dTMS) platform technology. Each application of this technology targets specific conditions, providing a noninvasive alternative to traditional treatments. The range of disorders addressed includes:

  • Major Depressive Disorders: A treatment designed to mitigate the symptoms of depression, offering hope for patients who have not responded well to conventional treatment methods.
  • Anxious Depression: Tailored to manage the symptoms of depression accompanied by anxiety, providing a dual approach to treatment.
  • Obsessive-Compulsive Disorders (OCD): Aims at reducing the severity of OCD symptoms, offering patients a path to regain control over their compulsions and obsessions.
  • Smoking Addiction: Utilized as a therapeutic measure to help individuals overcome nicotine dependence and addiction, promoting healthier lifestyle choices.
  • Bipolar Disorders: Addresses the extreme mood swings associated with bipolar disorder, helping to stabilize emotions.
  • Post Traumatic Stress Disorders (PTSD): Offers relief for the symptoms of PTSD, aiding individuals in the coping process after traumatic events.
  • Schizophrenia: Focuses on alleviating some of the cognitive and affective symptoms related to schizophrenia, potentially improving quality of life.
  • Alzheimer's Disease: Explored as a treatment to possibly slow down or alleviate some of the cognitive decline associated with Alzheimer's disease.
  • Autism: Investigated for its potential to improve outcomes in individuals on the autism spectrum, focusing on enhancing communication abilities and behavioral symptoms.
  • Chronic Pain: A treatment option for managing chronic pain conditions, aiming to reduce pain intensity and improve daily functioning.
  • Multiple Sclerosis: Applied as a part of comprehensive care in managing symptoms associated with multiple sclerosis, potentially improving mobility and quality of life.
  • Post Stroke Rehabilitation: Implemented in the rehabilitation process post-stroke, focusing on restoring lost functions and accelerating recovery.
  • Parkinson's Diseases: Offers a treatment avenue for managing symptoms of Parkinson's disease, such as tremors and rigidity, aiming to enhance patient autonomy.

Contact Information

Address: Bynet Building
Phone: 972 2 582 4030